Monday, July 9, 2012

GlaxoSmithKline pleads guilty to health fraud

Attorneys for British drugmaker GlaxoSmithKline leave U.S. District Court in Boston Thursday, July 5, 2012 after an agreement by the company to pay $3 billion for criminal and civil violations involving 10 drugs that are taken by millions of people was approved by a federal judge. It is the largest health care fraud settlement in U.S. history. (AP Photo/Elise Amendola)

Attorneys for British drugmaker GlaxoSmithKline leave U.S. District Court in Boston Thursday, July 5, 2012 after an agreement by the company to pay $3 billion for criminal and civil violations involving 10 drugs that are taken by millions of people was approved by a federal judge. It is the largest health care fraud settlement in U.S. history. (AP Photo/Elise Amendola)

File- In this Nov. 5, 2008 file photo passers-by walk past the American headquarters of British drug maker GlaxoSmithKline PLC, in Philadelphia. A federal judge in Boston approved Thursday, July 5, 2012 to an agreement by British drugmaker GlaxoSmithKline to pay $3 billion for criminal and civil violations involving 10 drugs, marking the largest health care fraud settlement in U.S. history. (AP Photo/Matt Rourke, File)

FILE - In this June 30, 2010 file photo, a pharmacist holds a bottle of the drug Avandia at Maximart Pharmacy in Palo Alto, Calif. GlaxoSmithKline on Thursday, July 5, 2012, in U.S. District Court in Boston pleaded guilty to failing to report to the government some safety problems with diabetes drug Avandia. The company also pleaded guilty to promoting popular antidepressants Paxil and Wellbutrin for unapproved uses. (AP Photo/Paul Sakuma, file)

(AP) ? A federal judge on Thursday approved an agreement by British drugmaker GlaxoSmithKline to pay $3 billion for criminal and civil violations involving 10 drugs, the largest health care fraud settlement in U.S. history.

The amount of money involved led U.S. District Judge Rya Zobel to remark in court that she was having trouble keeping track of the numbers.

GlaxoSmithKline pleaded guilty to promoting the popular antidepressants Paxil and Wellbutrin for unapproved uses.

Government officials said in the original complaint that the company promoted Paxil as safe for children and adolescents, even though the U.S. Food and Drug Administration hadn't approved it for those patients and the company's clinical trials raised concerns about an increased suicide risk.

Prosecutors had charged that the drugmaker promoted Wellbutrin for unapproved uses that included treating attention deficit disorder, bipolar disorder, obesity, sexual dysfunction and anxiety when it wasn't shown to be safe and effective for those uses.

The company also admitted that it failed to report to the government some safety problems with Avandia. In 2010, the diabetes drug was restricted in the U.S. and banned in Europe after it was found to sharply increase the risks of heart attacks and congestive heart failure.

Defense lawyer Geoffrey Hobart and Assistant U.S. Attorney Sara Bloom declined to comment immediately following Thursday's hearing.

A GlaxoSmithKline spokesman referred later to comments CEO Sir Andrew Witty made Monday, including that the company has learned "from the mistakes that were made."

When the government announced the settlement Monday, U.S. Deputy Attorney General James M. Cole called it historic, saying it sent a clear warning to any company that chooses to break the law.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/bbd825583c8542898e6fa7d440b9febc/Article_2012-07-05-Justice-GlaxoSmithKline/id-8fb6393713994fe9b9e5db9a89624556

critics choice awards 2012 colbert president huntingtons disease rob the firm new york philharmonic marines urinating on taliban

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.